Alzheimer's disease and diabetes: New insights and unifying therapies

Current Diabetes Reviews

Volumn 9, Issue 3, 2013, Pages 218-227

  Vignini, Arianna ^a   Giulietti, Alessia ^a   Nanetti, Laura ^a   Raffaelli, Francesca ^a   Giusti, Lucia ^a   Mazzanti, Laura ^a   Provinciali, Leandro ^b  

^a Section of Biochemistry   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Alzheimer's disease; Liraglutide; Metformin; Statins; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; ATORVASTATIN; CHOLESTEROL; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LIRAGLUTIDE; METFORMIN; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; PYRIDOXAMINE; SIMVASTATIN; TENILSETAM;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; ARTICLE; ASTROCYTOMA; CARDIOVASCULAR RISK; COGNITION; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DRUG EFFECT; GLUCOSE METABOLISM; HUMAN; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MILD COGNITIVE IMPAIRMENT; NERVE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SENILE PLAQUE; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; METFORMIN; RECEPTOR, INSULIN; RISK FACTORS; TAU PROTEINS;

EID: 84878643703     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399811309030003     Document Type: Article

References (103)

1. Clark MJ, Sterrett JJ, Carson DS. Diabetes Guidelines: A Summary and comparison of the recommendations of the American Diabetes Association, Veterans Health Administration, and American Association of Clinical Endocrinologists. Clinical Therapeutics 2000; 22: 899-910.
2. Triplitt CL. Examining the mechanisms of glucose regulation. Am J Manag Care 2012; 18(1 Suppl): 4supp-10
3. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29 Suppl 1: S43-8.
4. Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosc 2000; 23: 542-9.
5. White MF, Ronald Kahn C. The insulin signaling system. J Biol Chem 1994. 7: 1-4.
6. Czech MP. The nature and regulation of the insulin receptor: structure and function. Annu Rev Physiol 1985; 47: 357-81.
7. Chiefari E, Nevolo MT, Arcidiacono B, et al. HMGA1 is anovel downstream nuclear target of the insulin receptor signaling pathway. Sci Rep 2012. 2: 251.
8. Ritchie K, Lovestone S. The dementias. Lancet 2002; 360: 1759-66.
9. Picone P, Giacomazza D, Vetri V, et al. Insulin-activated Akt rescues Aβ oxidative stress-induced cell death by orchestrating molecular trafficking. Aging Cell 2011. 10: 832-43.
10. Zhang H, Ma Q, Zhang Y, Xu H. Proteolytic processing of Alzheimer's β-amyloid precursor protein. J Neurochem 2012. 120(Suppl.1): 9-21.
11. Kang J, Lemaire HG, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325: 733-6.
12. Burdick D, Soreghan B, Kwon M, et al. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem 1992; 267: 546-54.
13. Jarrett JT, Berger EP, Lansbury PT. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993; 32: 4693-97.
14. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994; 13: 45-53.
15. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184-5.
16. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
17. Wang X, Zheng W, Xie JW, et al. Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficts in an Alzheimer transgenic mouse model. Mol Neurodegener 2010; 5: 46.
18. Plaschke K, Kopitzb J, Siegelinc M, et al. Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AβPP-overexpressing mice. J Alzheimer's Dis 2010; 19691-704.
19. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53(9): 1937-42.
20. Xu WL, von Strauss E, Qiu CX, Winbland B. Uncontolled diabetes increase the risk of Alzheimer's disease: a population-based cohort study. Diabetologia 2009; 52: 1031-39.
21. Rönnemaa E, Zethelius B, Sundelöf J, et al. Impaired insulin secretion increases the risk of Alzheimer disease Neurology 2008; 71(14): 1065-71.
22. Irie F, Fitzpatrick AL, Lopez OL, et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. Arch Neurol 2008; 65(1): 89-93.
23. Frolich L, Blum-Degen D, Bernstein HG, et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 1998; 105: 423-38.
24. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol 2011; 225: 54-62.
25. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulinlike growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 2005; 7: 63-80.
26. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 2005; 8: 247-68.
27. Baker LD, Frank LL, Foster-Schubert K, et al. Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease. J Alzheimers Dis 2010; 22(2): 569-79.
28. Craft S, Stennis Watson G. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004; 3: 169-78.
29. Craft S, Newcomer J, Kanne S, et al. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging 1996; 17: 123-30.
30. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol 2011; 225: 54-62.
31. Schechter R, Abboud M. Neuronal synthesized insulin roles on neural differentiation within fetal rat neuron cell cultures. Brain Res Dev Brain Res 2001; 127: 41-49.
32. Schechter R, Beju D, Gaffney T, Schaefer F, Whetsell L. Preproinsulin I and II mRNAs and insulin electron microscopic immunoreaction are present within the rat fetal nervous system. Brain Res 1996; 736: 16-27.
33. Banks WA. The source of cerebral insulin. Eur J Pharmacol 2004; 490: 5-12.
34. Mosconi L, Pupi A, De Leo MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 2008; 1147: 180-95.
35. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX. OGlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A. 2004; 101(29): 10804-9.
36. Iqball K, Liu F, Gong CX, del C. Alonso A, Inge Grundke-Iqball I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009; 118(1): 53-69.
37. Jolivalt CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, Masliah E. Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Experiment Neurol 2010; 223: 422-31.
38. Park SA. A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. J Clin Neurol 2011; 7:10-18.
39. Moreira PI, Santos MS, Sena C, Seic Ŗ Oliveira CR. Insulin protects against amyloid β-peptide toxicity in brain mitochondria of diabetic rats. Neurobiology of Disease 2005; 18(3): 628-37.
40. Di Carlo M, Picone P, Carrotta R, Giacomazza D, San Biagio PL. Insulin Promotes Survival of Amyloid-Beta Oligomers Neuroblastoma Damaged Cells via Caspase 9 Inhibition and Hsp70 Upregulation. J Biomed Biotechnol 2010; 2010: 147835.
41. Dudek H, Datta SR, Franke TF, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997; 275: 661-665.
42. Lee HK, Kumar P, Fu Q, Rosen KM, Querfurth HW. The Insulin /Akt signaling pathway is targeted by intracellular b-amyloid. Mol Biol Cell 2009; 20: 1533-44.
43. Muchowski PJ, Schaffar G, Sittler A, Wanker EE, Hayer-Hartl MK, Hartl FU. Hsp70 and Hsp40 chaperones can inhibit selfassembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci U S A 2000; 97(14): 7841-46.
44. Dul JL, Davis DP, Williamson EK, Stevens FJ, Argon Y. Hsp70 and antifibrillogenic peptides promote degradation and inhibit intracellular aggregation of amyloidogenic light chains. J Cell BioloL 2001; 152(4): 705-15.
45. Devi L, Alldred MJ, Ginsberg SD, Ohno M. Mechanisms underlying insulin deficiency-induced acceleration of b-amyloidosis in a mouse model of Alzheimer's Disease. PloS One 2012; 7(3): e32792.
46. Craft S, Asthana S, Cook DG, et al. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 2003; 28: 809-22.
47. Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates betaamyloid in early AD. Neurology 2008; 70: 440-8.
48. Benedict C, Hallschmid M, Hatke A, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004; 29: 1326-34.
49. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004; 127: 481-96.
50. Gupta A, Bisht B, Sankar Dey C. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's- like changes. Neuropharmacology 2011; 60: 910-20.
51. Zhao WQ, Alkon DL. Role of insulin and insulin receptor in learning and memory. Molecular and Cellular Endocrinology 2001; 177: 125-34.
52. Kickstein E, Krauss S, Thornhill P, et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S A 2010; 107(50): 21830-5.
53. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-5.
54. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009. 52: 1766-77.
55. Chen Y, Zhoua K, Wang R, et al. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A 2009; 106(10): 3907-12.
56. McClean PL, Gault VA, Harriott P, Hölscher C. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease. Eur J Pharmacol 2010; 630: 158-62
57. Gault VA, Flatt PR, O'Harte FP. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun 2003; 308: 207-13.
58. Sarkar S, Fekete C, Legradi G, Lechan RM. Glucagon like peptide- 1 (7-36) amide (GLP-1) nerve terminals densely innervate corticotropin- releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res 2003; 985: 163-68.
59. Abbas T, Faivre E, Hölscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res 2009; 205: 265-71.
60. Gengler S, Gault V, Jucker M, Holscher C. Val(8)GLP-1, a protease- resistant incretin analogue, prevents the impairment of hippocampal synaptic plasticity in an APP/PS-1 mouse model of Alzheimer's disease. Annual Soc Neurosci meeting 2008; 38.
61. Radde R, Bolmont T, Käser S, et al. Aß42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 2006; 7: 940-7.
62. Han WN, Hölscher C, Yuan L, et al. Liraglutide protects against amyloid-protein-induced impairment of spatial learning and memory in rats. Neurobiol Aging 2012. (In press)
63. Horowitz M, Flint A, Jones KL, et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract 2012. (In press)
64. McClean PL, Parthsarathy V, Faivre E, Holscher C. The Diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's Disease. J Neurosc 2011; 31(17): 6587-6594.
65. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434-44.
66. Khalil A, Berrougui H, Pawelec G, Fulop T. Impairment of the ABCA1 and SR-BI-mediated cholesterol efflux pathways and HDL anti-inflammatory activity in Alzheimer's disease. Mech Ageing Dev 2012; 133(1): 20-9.
67. Frisardi V, Panza F, Solfrizzi V, Seripa D, Pilotto A. Plasma lipid disturbances and cognitive decline. J Am Geriatr Soc 2010; 58: 2429-30.
68. Panza F, Solfrizzi V, D'Introno A, et al. Higher total cholesterol, cognitive decline, and dementia. Neurobiol Aging 2009; 30: 546-8.
69. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3- hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-43.
70. Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterollowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2001; 8: 890-9.
71. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999; 159:2661-7.
72. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucoseintolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in the cholesterol and recurrent events (CARE) trial: the CARE Investigators. Circulation 1998; 98: 2513-9.
73. Keech A, Colquhoun D, Best J. LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose. Diabetes Care 2003; 26(10): 2713-21.
74. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention study. Circulation 2001; 103(3): 357-62.
75. Pfrieger FW. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? BioEssays 2003; 25: 72-8.
76. Koudinov AR, Koudinova NV. Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J 2001; 15: 1858-60.
77. Koudinov AR, Koudinova NV. Cholesterol homeostasis failure as a unifying cause of synaptic degeneration. J Neurol Sci 2005; 229- 30: 233-40.
78. Pac-Soo C, Lloyd DG, Vizcaychipi MP, Ma D. Statins: the role in the treatment and prevention of Alzheimer's neurodegeneration. J Alzheimers Dis 2011; 27(1): 1-10.
79. Höglund K, Blennow K. Effect of HMG-CoA Reductase Inhibitors on [beta]-Amyloid Peptide Levels: Implications for Alzheimer's Disease. CNS Drugs 2007; 21(6): 449-62.
80. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the _-secretase ADAM 10. Proc Natl Acad Sci USA. 2001; 98(10): 5815-5820.
81. Johnson-Anuna LN, Eckert GP, Keller JH, et al. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther 2005; 312(2): 786-93.
82. Reid PC, Urano Y, Kodama T, Hamakubo T. Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med 2007; 11: 383-92.
83. Vetrivel KS, Thinakaran G. Membrane rafts in Alzheimer's disease beta-amyloid production. Biochim Biophys Acta 2010; 1801: 860-7.
84. Guardia-Laguarta C, Coma M, Pera M, et al. Mild cholesterol depletion reduces amyloid-beta production by impairing APP trafficking to the cell surface. J Neurochem 2009; 110: 220-30.
85. Hur JW, Behbahani H, Aoki H, et al. Active gamma-secretase is localized to detergent-resistant membranes in human brain. FEBS J 2008; 275: 1174-87.
86. Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci USA 2003; 100: 11735-40.
87. Kurata T, Miyazaki K, Kozuki M, et al. Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease. Neurol Res 2012. (In press)
88. Fonseca AC, Resende R, Oliveira CR, Pereira CM. Cholesterol and statins in Alzheimer's disease: current controversies. Exp Neurol 2010; 223(2): 282-93.
89. Sparks DL. Alzheimer disease: Statins in the treatment of Alzheimer disease. Nat Rev Neurol. 2011 Oct 18; 7(12): 662-3. doi: 10.1038/nrneurol.2011.165.
90. Sano M, Bell KL, Galasko D, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011; 77(6): 556-63.
91. Kroner Z. The relationship between Alzheimer's disease and Diabetes: Type 3 Diabetes? Altern Med Rev 2009; 14(4): 373-380.
92. Valente T, Gella A, Fernandez-Busquets X, Unzeta M, Durany N. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis 2010; 37(1): 67-76.
93. Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi M. Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2006; 21: 197-208.
94. Masayoshi T, Sho-ichi Y. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's Disease. J Alzheim Dis 2009; 16: 845-858.
95. Krautwald M, Münch G. Advanced glycation end products as biomarkers and gerontotoxins - A basis to explore methylglyoxallowering agents for Alzheimer's disease? Exper Gerontol 2010; 45: 744-751.
96. Takedo A, Yasuda T, Miyata T, et al. Immunohistochemical study of advanced glycation end products in aging and Alzheimer's disease brain. Neurosci Lett 1996; 221: 17-20.
97. Srikanth V, Maczurek A, Phan T, et al. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiology of Aging 2011; 32: 763-777.
98. Munch G, Mayer S, Michaelis J, et al. Cunningham Influence of advanced glycation end-products and AGE-inhibitors on nucleation- dependent polymerization of β-amyloid peptide. Biochimica et Biophysica Acta 1997; 1360: 17-29.
99. Carvalho VF, Florim LT, Barreto E, et al. Inhibition of advanced glycation end products by aminoguanidine restores mast cell numbers and reactivity in alloxan-diabetic rats. European Journal of Pharmacology 2011; 669: 143-148.
100. Brownlee M. Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 1994; 43: 836-841.
101. Rahbar S, Figarola JL. Novel inhibitors of advanced glycation endproducts. Archives of Biochemistry and Biophysics 2003; 419: 63-79.
102. Iacovella G, Alderson N, Thorpe S, Baynes J. The role of reactive α-dicarbonyls in AGE/ALE formation and implication in diabetic complications. SCJMM 2004; 5: 73-101.
103. Hoffmann J, Alt A, Lin J, et al. Tenilsetam prevents early diabetic retinopathy without correcting pericyte loss. Thromb Haemost 2006; 95(4): 689-95.